ES2124303T3 - Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. - Google Patents

Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.

Info

Publication number
ES2124303T3
ES2124303T3 ES93907548T ES93907548T ES2124303T3 ES 2124303 T3 ES2124303 T3 ES 2124303T3 ES 93907548 T ES93907548 T ES 93907548T ES 93907548 T ES93907548 T ES 93907548T ES 2124303 T3 ES2124303 T3 ES 2124303T3
Authority
ES
Spain
Prior art keywords
particles
drug
dosage forms
hydroxyethyl cellulose
stomach
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907548T
Other languages
English (en)
Inventor
John W Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Application granted granted Critical
Publication of ES2124303T3 publication Critical patent/ES2124303T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

TIPOS DE DOSIS MEDICINALES DE ADMINISTRACION ORAL Y LIBERACION SOSTENIDA QUE CONSISTEN EN UNA PASTILLA O CAPSULA CON UNA PLURALIDAD DE PARTICULAS DE UN FARMACO EN ESTADO SOLIDO DISPERSO EN CELULOSA DE ALQUILO TAL COMO HIDROXIETILCELULOSA O HIDROXIPROPILCELULOSA. UNA VEZ INGERIDA LA PASTILLA O CAPSULA ESTA SE DESINTEGRA PARA DISPERSAR LAS PARTICULAS EN EL ESTOMAGO DONDE EMBEBEN AGUA PARA AUMENTAR DE TAMAÑO Y PARA HACERSE MAS RESBALADIZAS, LO QUE AUMENTA SU RETENCION EN EL ESTOMAGO. EL AGUA EMBEBIDA DEL FLUIDO GASTRICO DISUELVE EL FARMACO ATRAPADO EN LAS PARTICULAS Y LA SOLUCION RESULTANTE SE DESPRENDE DE LAS PARTICULAS DISPERSAS, ASEGURANDO QUE NINGUN FARMACO SOLIDO, QUE PROVOCA MAS IRRITACIONES, ENTRE EN CONTACTO CON EL TEJIDO MUCOSO. SE PROPORCIONAN EJEMPLOS DE UNA SERIE DE ASPECTOS DE TIPOS DE DOSIS EN LOS QUE SE UTILIZAN DIFERENTES FARMACOS Y SE EXPLICAN LAS VENTAJAS. UN EJEMPLO ES LA ASPIRINA.
ES93907548T 1992-03-25 1993-03-17 Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. Expired - Lifetime ES2124303T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85832092A 1992-03-25 1992-03-25
US98695292A 1992-12-08 1992-12-08

Publications (1)

Publication Number Publication Date
ES2124303T3 true ES2124303T3 (es) 1999-02-01

Family

ID=27127455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907548T Expired - Lifetime ES2124303T3 (es) 1992-03-25 1993-03-17 Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.

Country Status (9)

Country Link
EP (1) EP0632720B1 (es)
JP (2) JPH07507059A (es)
AT (1) ATE173159T1 (es)
AU (1) AU668386B2 (es)
CA (1) CA2132012C (es)
DE (1) DE69322077T2 (es)
DK (1) DK0632720T3 (es)
ES (1) ES2124303T3 (es)
WO (1) WO1993018755A1 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
BR9507199A (pt) * 1994-03-24 1997-09-09 Procter & Gamble Cellulose Formas de dose sólidas contendo bismuto
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
AU707454B2 (en) * 1994-05-13 1999-07-08 Smithkline Beecham Corporation Method and composition for increasing calcium uptake
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
US5855915A (en) 1995-06-30 1999-01-05 Baylor University Tablets or biologically acceptable implants for long-term antiinflammatory drug release
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2002066952A2 (en) 2000-10-19 2002-08-29 Target Discovery, Inc Mass defect labeling for the determination of oligomer sequences
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
EP1558081A4 (en) 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2421524B1 (en) 2009-04-20 2018-08-08 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
WO2010129686A1 (en) 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
CN109745313A (zh) 2010-08-11 2019-05-14 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
KR20140114736A (ko) 2010-10-19 2014-09-29 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2601947A1 (en) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AU2013292519B2 (en) 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
CN105025854A (zh) 2013-01-07 2015-11-04 宾夕法尼亚大学董事会 治疗皮肤t细胞淋巴瘤的组合物和方法
EP3613861A1 (en) 2013-07-02 2020-02-26 EcoPlanet Environmental LLC Volatile organic compound formulations having antimicrobial activity
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015080943A1 (en) 2013-11-26 2015-06-04 Yale University Novel cell-penetrating compositions and methods using same
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US9982010B2 (en) 2014-04-07 2018-05-29 Women & Infants Hospital Of Rhode Island 7-dehydrocholesterol derivatives and methods using same
EP3182979B1 (en) 2014-08-20 2023-12-06 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
US10597368B2 (en) 2015-05-08 2020-03-24 Brown University Syringolin analogues and methods of making and using same
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
KR102207539B1 (ko) 2015-06-30 2021-01-26 네우라드 리미티드 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
US11135213B2 (en) 2015-10-28 2021-10-05 Yale University Quinoline amides and methods of using same
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CN109843379B (zh) 2016-09-01 2022-12-30 梅比斯发现公司 取代脲及其制备和使用方法
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
US10941126B2 (en) 2017-01-19 2021-03-09 Temple University-Of The Commonwealth System Of Higher Education Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
AU2018238138A1 (en) 2017-03-21 2019-10-17 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
EP3612184B1 (en) 2017-04-17 2024-06-05 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
CA3071345A1 (en) 2017-07-28 2019-01-31 Yale University Anticancer drugs and methods of making and using same
EP3716985A1 (en) 2017-11-27 2020-10-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2019147753A1 (en) 2018-01-24 2019-08-01 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
SG11202011534YA (en) 2018-05-29 2020-12-30 Cersci Therapeutics Inc Compounds for pain treatment, compositions comprising same, and methods of using same
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
JP2022521119A (ja) 2019-01-30 2022-04-06 サニフィット・セラピューティクス・ソシエダッド・アノニマ 組織の灌流の増加における使用のためのイノシトールリン酸化合物
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US11471507B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
MX2022015772A (es) 2020-06-09 2023-05-19 Inozyme Pharma Inc Proteínas enpp1 o enpp3 solubles y sus usos.
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
IT1250483B (it) * 1990-08-30 1995-04-07 Eurand Int Sistema di ritardo a matrice multipla
DE9107805U1 (es) * 1991-02-22 1991-09-05 Sopar S.A. Division Pharma, Sart Dame Avelines, Be

Also Published As

Publication number Publication date
JPH07507059A (ja) 1995-08-03
WO1993018755A1 (en) 1993-09-30
EP0632720A1 (en) 1995-01-11
CA2132012C (en) 2003-04-22
EP0632720B1 (en) 1998-11-11
CA2132012A1 (en) 1993-09-30
AU3811493A (en) 1993-10-21
DE69322077D1 (de) 1998-12-17
JP2004203897A (ja) 2004-07-22
DK0632720T3 (da) 1999-07-26
ATE173159T1 (de) 1998-11-15
DE69322077T2 (de) 1999-04-08
AU668386B2 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
ES2124303T3 (es) Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
FI914765A0 (fi) Foerdroejt frigoerande oral medicindosform.
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
ES2173891T3 (es) Sistema de liberacion pulsatil de un farmaco multiparticulado.
PT941071E (pt) Formas de dosagem farmaceuticas orais retidas no estomago para a libertacao controlada de farmacos fracamente soluveis e materia insoluvel
ATE530173T1 (de) Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
TR200102881T2 (tr) Balık jelatini içeren hızlı çözünen dozaj formları.
TR200001761T2 (tr) Çoklu terapilerde aktif esasların tatbiki için bir çift kapsül.
AU1301199A (en) Drug delivery systems utilizing liquid crystal structures
RU97115570A (ru) Применение неорганических аэрогелей в фармации
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
KR880002529A (ko) 혈전증 치료용 약학적 조성물 및 이의 제조방법
GB1432784A (en) Orally administrable pharmaceutical compositions
IT1240768B (it) Composizione farmaceutica contenente ranitidina sotto forma di capsule di gelatina.
Vasave A REVIEW ON: FLOATING DRUG DELIVERY SYSTEM
IE65251B1 (en) Controlled release capsules
BR0109917A (pt) Método de administração oral e composição para medicamentos sólidos ou suplementos dietéticos
Bhoyar et al. An overview of a gastro retentive floating drug delivery system
US6663896B1 (en) Delayed release aspirin for vascular obstruction prophylaxis
Raza et al. Various formulation variables effecting floatation behaviour of single unit gastroretentive capsules of ofloxacin
Kumar et al. Floating Drug Delivery System: A New Approach
Laxmi et al. Floating drug delivery approaches for prolonged gastric retention
IE33949L (en) Therapeutic composition
JPS6253918A (ja) 柱状の有効成分含有部分を埋没させた錠剤

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 632720

Country of ref document: ES